TMCnet News
Talaris Therapeutics Announces Upcoming Presentations at American Transplant Congress
BOSTON and LOUISVILLE, Ky., May 02, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, today announced upcoming data presentations at the American Transplant Congress (ATC) taking place June 4-8, 2022. In oral presentations at ATC, Talaris will share data from continued long-term follow-up of patients treated in the Company’s Phase 2 study of FCR001, as well as findings from urinary cell mRNA profiling of a subgroup of Phase 2 patients. A planned poster presentation will reflect the results of a real-world evidence analysis of the long-term health outcomes of Phase 2 patients treated with FCR001 compared to a cohort of matched patients treated with standard-of-care immunosuppression. Two additional poster presentations will provide updated data on COVID-19 outcomes among patients in the Phase 2 study, and in vivo findings on the immune cell types involved in rejection of allogeneic bone marrow transplant. Title: “Identification of a Unique and Mechanistic Urinary Cell mRNA Signature in Tolerant Kidney Transplant Recipients Conditioned with FCR001 Facilitating Cells” Title: “Long-Term Follow-Up of a Phase 2 Clinical Trial to Induce Tolerance in Living Donor Kidney Transplant Recipients” Poster presentations: Title: “Experience With COVID-19 Infection and Vaccination in Combined Kidney/HSCT Recipients” Title: “Fc? Receptor-Positive Cells Play a Critical Role in Rejection of Allogeneic Bone Marrow Cells Mediated by Anti-Donor Antibodies” Title: “The Promise of Tolerance in Living Donor Kidney Transplant (LDKT): A Retrospective, Real-World Assessment of the Safety and Efficacy of LDKT with FCR001 Investigational Cell-Therapy Compared with Standard of Care (SOC)” About Talaris Therapeutics Media Contact Investor Contact |